MOUNTAIN VIEW, Calif.,
Jan. 6, 2016 /PRNewswire/
-- Omnicell, Inc. (NASDAQ: OMCL) ("Omnicell"), a leading
provider of medication and supply management solutions to health
care systems, today announced that it completed its acquisition of
Aesynt Holding Coöperatief U.A. from Aesynt Holding, L.P. and
Aesynt, Ltd. on January 5, 2016,
pursuant to the terms and conditions of the Securities Purchase
Agreement announced on October 29,
2015. The combined company will support approximately 4,000
acute care facilities worldwide, have annual revenues of over
$670 million and have approximately
2,200 employees.
Randall A. Lipps, Founder,
Chairman, President and CEO Omnicell, said, "We are excited to
bring together these two companies, providing our health care
customers with an unprecedented choice of technology. This is a
major milestone in the 24-year history of Omnicell, as we continue
our singular focus on simplifying medication management throughout
the health care continuum. The addition of Aesynt to the Omnicell
family will add distinct capabilities in central pharmacy robotics,
IV robotics, automated dispensing systems, and analytics. The
strength of our combined offerings will deliver truly scalable
innovation to support safe and efficient health care. Our common
goal to improve health care for everyone will now be closer to
achievement."
Details of this acquisition are included in an investor
presentation found in the investor relations section of our website
and can be accessed by clicking here. For the twelve months
ended September 30, 2015, Aesynt
reported revenue and adjusted EBITDA of $190
million and $23 million,
respectively, up from $182 million
and $20 million, respectively for the
twelve months ended June 30,
2015.
In connection with the acquisition, Omnicell entered into a
$400 million senior secured credit
facility with Wells Fargo Securities, LLC, as Sole Lead Arranger
and Wells Fargo Bank, National Association, as administrative
agent. The credit agreement provides for (a) a five-year
$200 million term loan facility, and
(b) a five-year revolving credit facility of $200 million. On January
5, 2016, Omnicell borrowed the full $200 million under the Term Loan Facility and
$55 million under the Revolving Credit Facility to complete
the acquisition of Aesynt and to pay related fees and
expenses.
Omnicell will provide updated financial guidance for 2016
including the Aesynt acquisition during a conference call to
discuss the Company's Fourth Quarter 2015 financial results in the
coming weeks.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including but not limited to statements relating to the acquisition
of Aesynt and the anticipated benefits thereof, the expected
combined operations of Omnicell and Aesynt and the availability of
the senior secured credit facility going forward. As such, they are
subject to the occurrence of many events outside Omnicell's control
and are subject to various risk factors that could cause actual
results to differ materially from those expressed or implied in any
forward-looking statement. Risks include, without limitation,
risks associated with the acquisition of Aesynt, such as the risk
that the businesses will not be integrated successfully, that such
integration may be more difficult, time-consuming or costly than
expected or that the expected benefits of the acquisition will not
occur; risks related to future opportunities and plans for the
combined company, including uncertainty of the expected financial
performance and results of the combined company following
completion of the acquisition, including anticipated non-GAAP
accretive results and revenue; disruption from the integration
process, making it more difficult to conduct business as usual or
maintain relationships with customers, employees or suppliers; the
calculation of, and factors that may impact the allocation of the
purchase price to the net assets acquired in accordance with
applicable accounting rules and methodologies; the possibility that
if Omnicell does not achieve the perceived benefits of the
acquisition of Aesynt as rapidly or to the extent anticipated by
financial analysts or investors, the market price of Omnicell's
shares could decline; and risks related to the incurrence of debt,
including potential impairment of our flexibility and access to
capital, increased interest obligations and potential that we may
default under the terms of the senior credit facility and may not
be able to borrow under the revolving credit facility. Other risks
that contribute to the uncertain nature of the forward-looking
statements include our ability to take advantage of the growth
opportunities in medication management across the spectrum of
health care settings from long term care to home care, our ability
to deliver scalable innovation to support safe and efficient health
care, unfavorable general economic and market conditions, risks to
growth and acceptance of our products and services, including
competitive conversions, and to growth of the clinical automation
and workflow automation market generally, the potential of
increasing competition, potential regulatory changes, the ability
of the company to improve sales productivity to grow product
bookings, to develop new products and to acquire and successfully
integrate companies. These and other risks and uncertainties are
described more fully in Omnicell's most recent filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on forward-looking
statements. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Omnicell
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
OMCL-G
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating
new efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire health care continuum—from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,200 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 7,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please
visit www.omnicell.com.
About Aesynt
Aesynt combines years of health care expertise with a
comprehensive portfolio of pharmacy automation and information
management tools. Aesynt partners with health care organizations to
fully optimize all medication forms enterprise-wide, driving
dramatic cost reductions and improved patient safety. With leading
solutions for sterile compounding, enterprise-wide inventory
management, and medication dispensing, Aesynt is committed to
developing innovative solutions to solve the most pressing
challenges for our global health care partners. For more
information, visit www.Aesynt.com or follow Aesynt on Twitter at
https://twitter.com/Aesynt or LinkedIn at www.linkedin.com/company/
Aesynt.
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design, are registered
trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or
registered trademarks of their respective companies.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-completes-acquisition-of-aesynt-300200182.html
SOURCE Omnicell, Inc.